Botanix Pharmaceuticals (BOT) has had its application to use the novel sofpironium bromide gel to treat primary axillary hyperhidrosis rejected by the US Food and Drug Administration (FDA).
Source: https://themarketherald.com.au/botanix-pharmaceuticals-asxbot-suffers-setback-in-fda-approval-for-sofpironium-bromide-gel-to-treat-hyperhidrosis-2023-09-26/
Bot Chart, page-10609
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $441.0M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.5¢ | 27.3¢ | $1.157M | 4.160M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 315228 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 644947 | 2 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
0.000 ( 1.75 %) |
||||
| Open | High | Low | Volume | ||
| 28.5¢ | 28.5¢ | 27.5¢ | 1471691 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| BOT (ASX) Chart |